Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 2—February 2019
Dispatch

Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil

Fernando A. Bozza1, Andres Moreira-Soto1, Alexandra Rockstroh, Carlo Fischer, Alessandra D. Nascimento, Andrea S. Calheiros, Christian Drosten, Patrícia T. Bozza, Thiago Moreno L. Souza, Sebastian Ulbert, and Jan Felix DrexlerComments to Author 
Author affiliations: National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil (F.A. Bozza, A.D. Nascimento); D’Or Institute for Research and Education, Rio de Janeiro (F.A. Bozza, A.D. Nascimento); Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany (A. Moreira-Soto, C. Fischer, C. Drosten, J.F. Drexler); Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany (A. Rockstroh, S. Ulbert); Instituto Oswaldo Cruz, Rio de Janeiro (A.S. Calheiros, P.T. Bozza); German Centre for Infection Research, Berlin (C. Drosten, J.F. Drexler); Center for Technological Development in Health, Rio de Janeiro (T.M.L. Souza); Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow, Russia (J.F. Drexler)

Main Article

Figure 2

Zika virus and CHIKV antibody dynamics among samples from patients in Brazil, 2016. A) Percentage seroconversion for markers of acute infection with Zika virus and CHIKV (IgM NS1–based Zika virus ELISA, IgM envelope-based Zika virus ELISA, IgM μ-capture Zika virus ELISA, IgA NS1-based Zika virus ELISA, IgM CHIKV ELISA) at any time point. B) Median ELISA ratios for Zika virus and CHIKV IgM and IgA over time. C) Percentage seroconversion for markers of convalescence after Zika virus and CHIKV infe

Figure 2. Zika virus and CHIKV antibody dynamics among samples from patients in Brazil, 2016. A) Percentage seroconversion for markers of acute infection with Zika virus and CHIKV (IgM NS1–based Zika virus ELISA, IgM envelope-based Zika virus ELISA, IgM μ-capture Zika virus ELISA, IgA NS1-based Zika virus ELISA, IgM CHIKV ELISA) at any time point. B) Median ELISA ratios for Zika virus and CHIKV IgM and IgA over time. C) Percentage seroconversion for markers of convalescence after Zika virus and CHIKV infection (IgG NS1-based Zika virus ELISA and IgG envelope-based Zika virus ELISA, Zika virus PRNT50, IgG CHIKV ELISA) at any time point. D) Median ELISA ratios for Zika virus and CHIKV IgG over time. Numbers of specimens per time point are shown in Figure 1. Dashed lines indicate signal-to-cutoff ratios of >1.1 considered positive for all ELISAs except μ-capture ELISA, for which the dashed line indicates a signal-to-cutoff ratio of >10, considered positive by the manufacturer. See Appendix Figure 5 for the percentage de novo seroconversion of Zika virus and CHIKV in different assays per time point. CHIKV, chikungunya virus; dpo, days post–symptom onset; E, envelope; NS, nonstructural protein; PRNT, plaque reduction neutralization test.

Main Article

1These authors contributed equally to this article.

Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external